Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.46 |
| ▸ | DAGLA | Q9Y4D2 | 6/20 | 0.45 |
| ▸ | ABHD6 | Q9BV23 | 5/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8565864 | 0.95 | MC4R (0.46) | SLC18A3 | |
| SCHEMBL11466316 | 0.95 | MC4R (0.46) | SLC18A3 | |
| SCHEMBL27304337 | 0.79 | HSD11B1 (0.45) | HSD11B1SLC18A3DAGLAABHD6DPP4 | |
| SCHEMBL2606119 | 0.79 | ADRA2A (0.53) | — | |
| SCHEMBL7413375 | 0.79 | HSD11B1 (0.45) | HSD11B1SLC18A3DAGLAABHD6 | |
| SCHEMBL4964339 | 0.78 | HSD11B1 (0.61) | HSD11B1DAGLAABHD6DPP4 | |
| SCHEMBL4629395 | 0.78 | HSD11B1 (0.61) | HSD11B1DAGLAABHD6DPP4 | |
| SCHEMBL11470450 | 0.77 | ADRA2A (0.51) | — | |
| Ammonia Solution, Strong SCHEMBL3645001 | 0.77 | ADRA2A (0.51) | — | |
| SCHEMBL27492 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015947-A1 | Cyclic hydroxylamine as psychoactive compounds | BTG INTERNATIONAL LIMITED (GB) | 2012-01-19 | — | — | US | disclosed |
| US-20120015947-A1 | Cyclic hydroxylamine as psychoactive compounds | BTG INTERNATIONAL LIMITED (GB) | 2012-01-19 | — | — | US | disclosed |
| US-20120015947-A1 | Cyclic hydroxylamine as psychoactive compounds | BTG INTERNATIONAL LIMITED (GB) | 2012-01-19 | — | — | US | disclosed |
| US-8053432-B2 | Cyclic hydroxylamine as psychoactive compounds | BTG INTERNATIONAL LIMITED (GB) | 2011-11-08 | — | — | US | disclosed |
| US-8053432-B2 | Cyclic hydroxylamine as psychoactive compounds | BTG INTERNATIONAL LIMITED (GB) | 2011-11-08 | — | — | US | disclosed |
| US-8053432-B2 | Cyclic hydroxylamine as psychoactive compounds | BTG INTERNATIONAL LIMITED (GB) | 2011-11-08 | — | — | US | disclosed |
| US-7842690-B2 | Cyclic hydroxylamine as psychoactive compounds | BTG INTERNATIONAL LIMITED (GB) | 2010-11-30 | — | — | US | disclosed |
| US-7842689-B2 | suitable for the treatment of anxiety and depression; 2-(4-hydroxymorpholin-3-yl)cyclohex-2-en-1-one; anxiolytic agents; antidepressants | BTG INTERNATIONAL LIMITED (GB) | 2010-11-30 | — | — | US | disclosed |
| US-7842689-B2 | suitable for the treatment of anxiety and depression; 2-(4-hydroxymorpholin-3-yl)cyclohex-2-en-1-one; anxiolytic agents; antidepressants | BTG INTERNATIONAL LIMITED (GB) | 2010-11-30 | — | — | US | disclosed |
| US-7842689-B2 | suitable for the treatment of anxiety and depression; 2-(4-hydroxymorpholin-3-yl)cyclohex-2-en-1-one; anxiolytic agents; antidepressants | BTG INTERNATIONAL LIMITED (GB) | 2010-11-30 | — | — | US | disclosed |
| US-20090312329-A1 | Cyclic hydroxylamine as psychoactive compounds | BTG INTERNATIONAL LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| EP-1631557-B1 | CYCLIC HYDROXYLAMINE AS PSYCHOACTIVE COMPOUNDS | BTG INT LTD (GB) | 2006-12-20 | — | — | EP | disclosed |
| US-20060142286-A1 | Cyclic hydroxylamine as psychoactive compounds | BTG INTERNATIONAL LIMITED (GB) | 2006-06-29 | — | — | US | disclosed |
| EP-1631557-A1 | CYCLIC HYDROXYLAMINE AS PSYCHOACTIVE COMPOUNDS | BTG INTERNATIONAL LIMITED (GB) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004111021-A1 | CYCLIC HYDROXYLAMINE AS PSYCHOACTIVE COMPOUNDS | BTG INTERNATIONAL LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004111021-A1 | CYCLIC HYDROXYLAMINE AS PSYCHOACTIVE COMPOUNDS | BTG INTERNATIONAL LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
| EP-0747357-B1 | Dihydropyridine NPY antagonists: piperidine derivatives | BRISTOL MYERS SQUIBB CO (US) | 2002-01-09 | — | — | EP | disclosed |
| US-5668151-A | USEFUL AS ANOREXIGENIC AGENTS IN PROMOTING WEIGHT LOSS AND TREATING EATING DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-09-16 | — | — | US | disclosed |
| EP-0747357-A2 | Dihydropyridine NPY antagonists: piperidine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-11 | — | — | EP | disclosed |
| US-4031221-A | ANALGESICS, TRANQUILIZERS, INDOLE COMPOUNDS | AMERICAN HOECHST CORPORATION (US) | 1977-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015947-A1 | Cyclic hydroxylamine as psychoactive compounds | HTR1A, HTR1D, OPRM1 | HSD11B1 91/4885SLC18A3 292/4885DAGLA 4331/4885 |
| US-20090312329-A1 | Cyclic hydroxylamine as psychoactive compounds | HTR1A, HTR2C, OPRM1 | HSD11B1 114/4885SLC18A3 178/4885DAGLA 4231/4885 |
| US-20060142286-A1 | Cyclic hydroxylamine as psychoactive compounds | HTR1A, HTR2C, OPRM1 | HSD11B1 114/4885SLC18A3 178/4885DAGLA 4231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.